HK1207638A1 - 抗病毒化合物 - Google Patents

抗病毒化合物

Info

Publication number: HK1207638A1
Authority: HK; Hong Kong
Prior art keywords: antiviral compounds; antiviral; compounds
Prior art date: 2009-05-13

Application number

HK15108271.6A

Other languages

English (en)

Inventor

Hongyan Guo

Darryl Kato

Thorstens A Kirschberg

Hongtae Liu

John O Link

Michael L Mitchell

Jay P Parrish

Neil Squires

Jianyu Sun

James Taylor

Elizabeth M Bacon

Eda Canales

Aesop Cho

Jeromy J Cottell

Manoj C Desai

Randall L Halcomb

Evan S Krygowski

Scott E Lazerwith

Qi Liu

Richard Mackman

Hyung-Jung Pyun

Joseph H Saugier

James D Trenkle

Winston C Tse

Randall W Vivian

Scott D Schroeder

William J Watkins

Lianhong Xu

Zheng-Yu Yang

Terry Kellar

Xiaoning Sheng

Michael Oneil Hanrahan Clarke

Chien-Hung Chou

Michael Graupe

Haolun Jin

Ryan Mcfadden

Michael R Mish

Samuel E Metobo

Barton W Phillips

Chandrasekar Venkataramani

Chuong U Kim

Original Assignee

Gilead Pharmasset Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-05-13

Filing date

2012-04-02

Publication date

2016-02-05

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42645241&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1207638(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2012-04-02 Application filed by Gilead Pharmasset Llc filed Critical Gilead Pharmasset Llc

2016-02-05 Publication of HK1207638A1 publication Critical patent/HK1207638A1/zh

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Virology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Peptides Or Proteins (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

HK15108271.6A 2009-05-13 2012-04-02 抗病毒化合物 HK1207638A1 (zh)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date
US17797209P	2009-05-13	2009-05-13
US22474509P	2009-07-10	2009-07-10
US23876009P	2009-09-01	2009-09-01

Publications (1)

Publication Number	Publication Date
HK1207638A1 true HK1207638A1 (zh)	2016-02-05

Family

ID=42645241

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
HK15108271.6A HK1207638A1 (zh)	2009-05-13	2012-04-02	抗病毒化合物
HK12103256.9A HK1162518A1 (zh)	2009-05-13	2012-04-02	抗病毒化合物
HK16111614.5A HK1223365A1 (zh)	2009-05-13	2016-10-06	抗病毒化合物
HK18112717.7A HK1253517B (zh)	2009-05-13	2018-10-05	抗病毒化合物

Family Applications After (3)

Application Number	Title	Priority Date	Filing Date
HK12103256.9A HK1162518A1 (zh)	2009-05-13	2012-04-02	抗病毒化合物
HK16111614.5A HK1223365A1 (zh)	2009-05-13	2016-10-06	抗病毒化合物
HK18112717.7A HK1253517B (zh)	2009-05-13	2018-10-05	抗病毒化合物

Country Status (40)

Country	Link
US (8)	US8088368B2 (zh)
EP (6)	EP3309157B1 (zh)
JP (7)	JP5582662B2 (zh)
KR (8)	KR20190029771A (zh)
CN (8)	CN109020961A (zh)
AP (2)	AP2016008993A0 (zh)
AR (1)	AR076765A1 (zh)
AU (1)	AU2010249043B2 (zh)
BR (3)	BRPI1010795B1 (zh)
CA (2)	CA2761258C (zh)
CL (1)	CL2011002825A1 (zh)
CO (1)	CO6470842A2 (zh)
CY (4)	CY1116942T1 (zh)
DK (3)	DK3002281T3 (zh)
EA (5)	EA021974B1 (zh)
EC (1)	ECSP11011517A (zh)
ES (4)	ES2548156T3 (zh)
FR (1)	FR16C0005I2 (zh)
HK (4)	HK1207638A1 (zh)
HR (3)	HRP20151000T8 (zh)
HU (4)	HUE025983T2 (zh)
IL (5)	IL216254A (zh)
LT (3)	LT3002281T (zh)
ME (3)	ME02916B (zh)
MX (6)	MX2011012058A (zh)
NL (1)	NL300796I2 (zh)
NO (3)	NO3002281T3 (zh)
NZ (3)	NZ619205A (zh)
PE (2)	PE20120509A1 (zh)
PL (4)	PL3002281T3 (zh)
PT (4)	PT2430014E (zh)
RS (3)	RS55249B8 (zh)
SG (2)	SG10201402280QA (zh)
SI (4)	SI2430014T1 (zh)
SM (3)	SMT201700570T1 (zh)
TW (7)	TWI465444B (zh)
UA (1)	UA121454C2 (zh)
UY (1)	UY32629A (zh)
WO (1)	WO2010132601A1 (zh)
ZA (1)	ZA201108436B (zh)

Families Citing this family (204)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT2604620T (pt)	2003-05-30	2016-08-18	Gilead Pharmasset Llc	Analogos de nucleósido fluorados modificados
KR101650956B1 (ko) *	2007-07-05	2016-08-24	어레이 바이오파마 인크.	Ａｋｔ 단백질 키나제 억제제로서의 피리미딜 시클로펜탄
DK2373172T3 (da) *	2008-12-03	2013-10-21	Presidio Pharmaceuticals Inc	Hcv-ns5a-hæmmere
US9120779B2 (en)	2008-12-03	2015-09-01	Presidio Pharmaceuticals, Inc.	Inhibitors of HCV NS5A
WO2010075380A1 (en)	2008-12-23	2010-07-01	Abbott Laboratories	Anti-viral compounds
RU2505540C2 (ru)	2008-12-23	2014-01-27	Эббви Инк.	Антивирусные соединения
US8314135B2 (en)	2009-02-09	2012-11-20	Enanta Pharmaceuticals, Inc.	Linked dibenzimidazole antivirals
US8637561B2 (en) *	2009-02-17	2014-01-28	Enanta Pharmaceuticals, Inc.	Linked diimidazole derivatives
US8394968B2 (en)	2009-02-17	2013-03-12	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US8188132B2 (en)	2009-02-17	2012-05-29	Enanta Pharmaceuticals, Inc.	Linked dibenzimidazole derivatives
TWI438200B (zh) *	2009-02-17	2014-05-21	必治妥美雅史谷比公司	Ｃ型肝炎病毒抑制劑
US8242156B2 (en)	2009-02-17	2012-08-14	Enanta Pharmaceuticals, Inc.	Linked dibenzimidazole derivatives
US20120040977A1 (en) *	2009-02-23	2012-02-16	Presidio Pharmaceuticals, Inc.	Inhibitors of hcv ns5a
US9765087B2 (en)	2009-02-27	2017-09-19	Enanta Pharmaceuticals, Inc.	Benzimidazole derivatives
US8673954B2 (en)	2009-02-27	2014-03-18	Enanta Pharmaceuticals, Inc.	Benzimidazole derivatives
US8101643B2 (en) *	2009-02-27	2012-01-24	Enanta Pharmaceuticals, Inc.	Benzimidazole derivatives
EP2410841A4 (en)	2009-03-27	2012-10-24	Presidio Pharmaceuticals Inc	SUBSTITUTED BICYCLIC HCV INHIBITORS
US8796466B2 (en)	2009-03-30	2014-08-05	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
TW201038559A (en) *	2009-04-09	2010-11-01	Bristol Myers Squibb Co	Hepatitis C virus inhibitors
US8143414B2 (en)	2009-04-13	2012-03-27	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
JP5734956B2 (ja)	2009-04-15	2015-06-17	アッヴィ・インコーポレイテッド	抗ウィルス化合物
AU2010240882B2 (en) *	2009-04-24	2014-10-23	Janssen Sciences Ireland Uc	Diaryl ethers
CA2760205A1 (en) *	2009-05-12	2010-11-18	Schering Corporation	Fused tricyclic aryl compounds useful for the treatment of viral diseases
SI2430014T1 (sl)	2009-05-13	2015-10-30	Gilead Pharmasset Llc	Protivirusne spojine
EP2435421A1 (en) *	2009-05-29	2012-04-04	Schering Corporation	Antiviral compounds composed of three aligned aryl moieties to treat diseases such as hepatitis c
US8211928B2 (en)	2009-05-29	2012-07-03	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US8138215B2 (en) *	2009-05-29	2012-03-20	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
EP2435424B1 (en) *	2009-05-29	2015-01-21	Merck Sharp & Dohme Corp.	Antiviral compounds composed of three linked aryl moieties to treat diseases such as hepatitis c
US8937150B2 (en)	2009-06-11	2015-01-20	Abbvie Inc.	Anti-viral compounds
US9394279B2 (en)	2009-06-11	2016-07-19	Abbvie Inc.	Anti-viral compounds
RS53856B1 (en) *	2009-06-11	2015-08-31	Abbvie Bahamas Ltd.	HETEROCYCLIC COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS
US8716454B2 (en)	2009-06-11	2014-05-06	Abbvie Inc.	Solid compositions
US8609648B2 (en)	2009-07-02	2013-12-17	Enanta Pharmaceuticals, Inc.	Hepatitis C virus inhibitors
EP2454254A2 (en)	2009-07-16	2012-05-23	Vertex Pharmaceuticals Incorporated	Benzimidazole analogues for the treatment or prevention of flavivirus infections
CA2768638A1 (en) *	2009-08-07	2011-02-10	Tibotec Pharmaceuticals	Bis-benzimidazole derivatives as hepatitis c virus inhibitors
EP2462136A1 (en) *	2009-08-07	2012-06-13	Janssen R&D Ireland	Phenyl ethynyl derivatives as hepatitis c virus inhibitors
WO2011028596A1 (en)	2009-09-04	2011-03-10	Glaxosmithkline Llc	Chemical compounds
US8822700B2 (en) *	2009-09-11	2014-09-02	Enanta Pharmaceuticals, Inc.	Hepatitis C virus inhibitors
WO2011031904A1 (en)	2009-09-11	2011-03-17	Enanta Pharmaceuticals, Inc	Hepatitis c virus inhibitors
US8759332B2 (en) *	2009-09-11	2014-06-24	Enanta Pharmaceuticals, Inc.	Hepatitis C virus inhibitors
US8927709B2 (en) *	2009-09-11	2015-01-06	Enanta Pharmaceuticals, Inc.	Hepatitis C virus inhibitors
US8703938B2 (en) *	2009-09-11	2014-04-22	Enanta Pharmaceuticals, Inc.	Hepatitis C virus inhibitors
WO2011031934A1 (en) *	2009-09-11	2011-03-17	Enanta Pharmaceuticals, Inc.	Hepatitis c virus inhibitors
US8815928B2 (en)	2009-09-11	2014-08-26	Enanta Pharmaceuticals, Inc.	Hepatitis C virus inhibitors
UA108211C2 (uk) *	2009-11-04	2015-04-10	Янссен Рід Айрленд	Бензімідазолімідазольні похідні
US20110269956A1 (en)	2009-11-11	2011-11-03	Bristol-Myers Squibb Company	Hepatitis C Virus Inhibitors
US20110274648A1 (en)	2009-11-11	2011-11-10	Bristol-Myers Squibb Company	Hepatitis C Virus Inhibitors
US20110281910A1 (en)	2009-11-12	2011-11-17	Bristol-Myers Squibb Company	Hepatitis C Virus Inhibitors
CN102482269B (zh) *	2009-12-04	2015-07-29	财团法人卫生研究院	脯氨酸衍生物
WO2011081918A1 (en)	2009-12-14	2011-07-07	Enanta Pharmaceuticals, Inc	Hepatitis c virus inhibitors
US8377980B2 (en)	2009-12-16	2013-02-19	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
AU2010330862B2 (en) *	2009-12-18	2015-06-25	Idenix Pharmaceuticals, Inc.	5,5-fused arylene or heteroarylene hepatitis C virus inhibitors
CN102791687B (zh) *	2009-12-18	2015-02-11	北京凯因科技股份有限公司	C型肝炎病毒复制的新型抑制剂
CN102883718A (zh) *	2009-12-24	2013-01-16	顶点制药公司	用于治疗或预防黄病毒感染的类似物
US8362020B2 (en)	2009-12-30	2013-01-29	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US8933110B2 (en)	2010-01-25	2015-01-13	Enanta Pharmaceuticals, Inc.	Hepatitis C virus inhibitors
KR20120107529A (ko)	2010-01-25	2012-10-02	이난타 파마슈티칼스, 인코포레이티드	Ｃ형 간염 바이러스 억제제
EP2528926A4 (en) *	2010-01-28	2013-06-19	Boehringer Ingelheim Int	HEPATITIS C INHIBITOR COMPOUNDS
US8178531B2 (en) *	2010-02-23	2012-05-15	Enanta Pharmaceuticals, Inc.	Antiviral agents
US8623814B2 (en) *	2010-02-23	2014-01-07	Enanta Pharmaceuticals, Inc.	Antiviral agents
JP2013521279A (ja) *	2010-03-04	2013-06-10	エナンタファーマシューティカルズインコーポレイテッド	Ｈｃｖ複製の阻害剤としての医薬併用剤
WO2011119860A1 (en) *	2010-03-24	2011-09-29	Vertex Pharmaceuticals Incorporated	Analogues for the treatment or prevention of flavivirus infections
CN102869657A (zh) *	2010-03-24	2013-01-09	沃泰克斯药物股份有限公司	用于治疗或预防黄病毒感染的类似物
WO2011127350A1 (en)	2010-04-09	2011-10-13	Enanta Pharmaceuticals, Inc.	Hepatitis c virus inhibitors
US9125904B1 (en)	2010-05-11	2015-09-08	Achillion Pharmaceuticals, Inc.	Biphenyl imidazoles and related compounds useful for treating HCV infections
WO2011150243A1 (en) *	2010-05-28	2011-12-01	Presidio Pharmaceuticals, Inc.	Inhibitors of hcv ns5a
WO2011153396A1 (en)	2010-06-04	2011-12-08	Enanta Pharmaceuticals, Inc	Hepatitis c virus inhibitors
US20130310427A1 (en) *	2010-06-09	2013-11-21	Presidio Pharmaceuticals, Inc.	Inhibitors of hcv ns5a protein
NZ605440A (en)	2010-06-10	2014-05-30	Abbvie Bahamas Ltd	Solid compositions comprising an hcv inhibitor
WO2012021704A1 (en)	2010-08-12	2012-02-16	Enanta Pharmaceuticals, Inc.	Hepatitis c virus inhibitors
US20120195857A1 (en) *	2010-08-12	2012-08-02	Bristol-Myers Squibb Company	Hepatitis C Virus Inhibitors
AR082619A1 (es) *	2010-08-13	2012-12-19	Hoffmann La Roche	Inhibidores del virus de la hepatitis c
BR112013004520A2 (pt)	2010-08-26	2016-06-07	Univ Emory	inibidores potentes e seletivos do virus da hepatite c
US8999967B2 (en)	2010-09-29	2015-04-07	Presidio Pharmaceuticals, Inc.	Tricyclic fused ring inhibitors of hepatitis C
SG10201509456SA (en) *	2010-11-17	2015-12-30	Gilead Pharmasset Llc	Antiviral compounds
RU2452735C1 (ru) *	2010-11-30	2012-06-10	Александр Васильевич Иващенко	Замещенные азолы, противовирусный активный компонент, фармацевтическая композиция, способ получения и применения
EP2651927A4 (en) *	2010-12-15	2014-06-04	Abbvie Inc	ANTIVIRAL CONNECTIONS
EP2651925A4 (en) *	2010-12-15	2014-06-18	Abbvie Inc	ANTI-VIRAL COMPOUNDS
EP2651923A4 (en) *	2010-12-15	2014-06-18	Abbvie Inc	ANTI-VIRAL COMPOUNDS
TW201306841A (zh)	2010-12-20	2013-02-16	Gilead Sciences Inc	治療ｃ型肝炎病毒（ｈｃｖ）之方法
WO2012087976A2 (en) *	2010-12-21	2012-06-28	Intermune, Inc.	Novel inhibitors of hepatitis c virus replication
US8552047B2 (en)	2011-02-07	2013-10-08	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
JP2012188400A (ja) *	2011-03-11	2012-10-04	Tosoh Corp	ジチエノベンゾジチオフェンの製造方法
WO2012122716A1 (en)	2011-03-17	2012-09-20	Merck Sharp & Dohme Corp.	Tetracyclic xanthene derivatives and methods of use thereof for treatment of viral diseases
US8835456B1 (en)	2011-03-18	2014-09-16	Achillion Pharmaceuticals, Inc.	NS5A inhibitors useful for treating HCV
US20120252721A1 (en) *	2011-03-31	2012-10-04	Idenix Pharmaceuticals, Inc.	Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
US9546160B2 (en) *	2011-05-12	2017-01-17	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US10201584B1 (en)	2011-05-17	2019-02-12	Abbvie Inc.	Compositions and methods for treating HCV
JP5669984B2 (ja)	2011-05-18	2015-02-18	エナンタファーマシューティカルズインコーポレイテッド	５−アザスピロ［２．４］ヘプタン−６−カルボン酸およびその誘導体の製造方法
AU2012262338B2 (en)	2011-05-27	2016-12-08	Achillion Pharmaceuticals, Inc.	Substituted Aliphanes, Cyclophanes, Heteraphanes, Heterophanes, Hetero-Heteraphanes and Metallocenes Useful for Treating HCV Infections
TWI482766B (zh)	2011-07-09	2015-05-01	Sunshine Lake Pharma Co Ltd	As a spiro compound for hepatitis C virus inhibitors
PH12014500312A1 (en)	2011-08-08	2014-03-31	Lupin Ltd	Imidazole derivatives as antiviral agents
WO2013025975A1 (en) *	2011-08-17	2013-02-21	Glaxosmithkline Llc	Combination treatments for hepatitis c
MX2014002171A (es) *	2011-08-24	2014-04-25	Glaxosmithkline Llc	Tratamientos de combinacion para hepatitis c.
WO2013030750A1 (en)	2011-09-01	2013-03-07	Lupin Limited	Antiviral compounds
PE20141056A1 (es) *	2011-09-16	2014-09-05	Gilead Pharmasset Llc	Metodos para el tratamiento de vhc
PH12014500832A1 (en)	2011-10-21	2022-12-02	Abbvie Inc	Methods for treating hcv
US8492386B2 (en)	2011-10-21	2013-07-23	Abbvie Inc.	Methods for treating HCV
JP5677646B2 (ja) *	2011-10-21	2015-02-25	アッヴィ・インコーポレイテッド	Ｈｃｖの治療に使用するためのｄａａの（例えばａｂｔ−０７２もしくはａｂｔ−３３３との）併用治療
US8466159B2 (en)	2011-10-21	2013-06-18	Abbvie Inc.	Methods for treating HCV
TWI577672B (zh)	2011-11-03	2017-04-11	施萬生物製藥研發Ｉｐ有限責任公司	Ｃ型肝炎病毒抑制劑
PT3431477T (pt)	2011-11-16	2020-12-15	Gilead Pharmasset Llc	Imidazolilimidazolos condensados como compostos antivirais
MX340033B (es)	2011-12-28	2016-06-21	Janssen Sciences Ireland Uc	Derivados heterobiciclicos como inhibidores del virus de la hepatitis c.
US9034832B2 (en)	2011-12-29	2015-05-19	Abbvie Inc.	Solid compositions
JP5781706B2 (ja) *	2011-12-29	2015-09-24	アッヴィ・アイルランド・アンリミテッド・カンパニー	Ｈｃｖ阻害剤を含む固体組成物
US9326973B2 (en)	2012-01-13	2016-05-03	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
CA2862755A1 (en)	2012-02-10	2013-08-15	Lupin Limited	Antiviral compounds with a dibenzooxaheterocycle moiety
KR20140129019A (ko)	2012-02-14	2014-11-06	유니버시티 오브 조지아 리서치 파운데이션, 인코포레이티드	플라비비리다에 감염의 치료를 위한 스피로[2.4]헵탄
ITMI20120424A1 (it)	2012-03-19	2013-09-20	Rottapharm Spa	Composti chimici
EP2850072B1 (en)	2012-04-25	2016-08-31	Theravance Biopharma R&D IP, LLC	Hepatitis c virus inhibitors
ME02682B (me)	2012-04-25	2017-06-20	Theravance Biopharma R&D Ip Llc	Jedinjenja piperazina-piperidina kao inhibitori virusa hepatitisa c
US20130309196A1 (en)	2012-05-16	2013-11-21	Gilead Sciences, Inc.	Antiviral compounds
US9079887B2 (en)	2012-05-16	2015-07-14	Gilead Sciences, Inc.	Antiviral compounds
US9056860B2 (en)	2012-06-05	2015-06-16	Gilead Pharmasset Llc	Synthesis of antiviral compound
US8969588B2 (en) *	2012-06-05	2015-03-03	Gilead Pharmasset Llc	Solid forms of an antiviral compound
TWI610916B (zh) *	2012-08-03	2018-01-11	廣東東陽光藥業有限公司	作爲丙型肝炎抑制劑的橋環化合物及其在藥物中的應用
TW201412709A (zh) *	2012-09-28	2014-04-01	Sunshine Lake Pharma Co Ltd	作為丙型肝炎抑制劑的螺環化合物及其在藥物中的應用
US9416139B2 (en)	2012-11-29	2016-08-16	Sunshine Lake Pharma Co., Ltd.	Spiro ring compound as hepatitis C virus (HCV) inhibitor and uses thereof
US9802949B2 (en)	2012-11-29	2017-10-31	Sunshine Lake Pharma Co., Ltd.	Fused ring compounds as hepatitis C virus inhibitors, pharmaceutical compositions and uses thereof
CN103848819B (zh) *	2012-11-29	2017-04-12	广东东阳光药业有限公司	作为丙型肝炎抑制剂的螺环化合物、药物组合物及它们在药物中的应用
CN103880823B (zh) *	2012-12-21	2017-12-05	广东东阳光药业有限公司	作为丙型肝炎抑制剂的螺环化合物及其在药物中的应用
MX351816B (es)	2013-01-31	2017-10-30	Gilead Pharmasset Llc	Formulacion de combinacion de dos compuestos antivirales.
RU2518369C1 (ru) *	2013-02-07	2014-06-10	Общество с ограниченной ответственностью "Интеллектуальный Диалог"	Алкил [2-(2-{5-[4-(4-{2-[1-(2-метоксикарбониламино-ацетил)-пирролидин-2-ил]-3н-имидазол-4-ил}-фенил)-бута-1,3-диинил]-1н-имидазол-2-ил}-пирролидин-1-ил)-2-оксо-этил]-карбамат, фармацевтическая композиция, лекарственное средство, способ лечения вирусных заболеваний
RU2507201C1 (ru) *	2013-02-07	2014-02-20	Александр Васильевич Иващенко	Алкил [(s)-1-((s)-2-{5-[4-(4-{2-[(s)-1-((s)-2-метоксикарбониламино-3-метил-бутирил)-пирролидин-2-ил]-3н-имидазол-4-ил}-бута-1,3-диинил)-фенил]-1н-имидазол-2-ил}-пирролидин-1-карбонил)-2-метил-пропил]-карбамат нафталин-1,5-дисульфонат, фармацевтическая композиция, лекарственное средство, способ лечения вирусных заболеваний
TW201439060A (zh) *	2013-02-27	2014-10-16	Sunshine Lake Pharma Co Ltd	作爲丙型肝炎抑制劑的橋環化合物及其藥物組合物和用途
US11484534B2 (en)	2013-03-14	2022-11-01	Abbvie Inc.	Methods for treating HCV
WO2014197400A1 (en)	2013-06-04	2014-12-11	Gilead Pharmasset Llc	Preventing and treating recurrence of hcv infection after liver transplant
CN111116563B (zh) *	2013-06-06	2023-07-04	上海爱博医药科技有限公司	抑制丙肝病毒的化合物、药物组合物及其应用
US20150023913A1 (en)	2013-07-02	2015-01-22	Bristol-Myers Squibb Company	Hepatitis C Virus Inhibitors
US9717712B2 (en)	2013-07-02	2017-08-01	Bristol-Myers Squibb Company	Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
US9775831B2 (en)	2013-07-17	2017-10-03	Bristol-Myers Squibb Company	Combinations comprising biphenyl derivatives for use in the treatment of HCV
PT3038601T (pt)	2013-08-27	2020-06-30	Gilead Pharmasset Llc	Formulação combinada de dois compostos antivirais
CN104418785A (zh) *	2013-09-05	2015-03-18	浙江九洲药业股份有限公司	一种药物中间体的制备方法
EP3046924A1 (en)	2013-09-20	2016-07-27	IDENIX Pharmaceuticals, Inc.	Hepatitis c virus inhibitors
CN104610272B (zh) *	2013-11-05	2017-03-29	上海唐润医药科技有限公司	环状黄酮或异黄酮类化合物及其用途
KR101561964B1 (ko)	2013-11-15	2015-10-20	한국과학기술연구원	옥사졸리디논 화합물 및 이를 포함하는 c형 간염 예방 또는 치료용 약학 조성물
US20150150897A1 (en)	2013-12-02	2015-06-04	Gilead Pharmasset Llc	Methods of treating hepatitis c virus infection in subjects with cirrhosis
CN104725365B (zh) *	2013-12-23	2019-02-26	南京圣和药业股份有限公司	丙型肝炎病毒抑制剂及其应用
TW201609785A (zh)	2013-12-23	2016-03-16	吉李德製藥公司	固體型之抗病毒化合物
US9512108B2 (en)	2013-12-31	2016-12-06	Nanjing Sanhome Pharmaceutical Co., Ltd.	9,9,10,10-Tetrafluoro-9,10-dihydrophenanthrene hepatitis C virus inhibitor and application thereof
WO2015103490A1 (en)	2014-01-03	2015-07-09	Abbvie, Inc.	Solid antiviral dosage forms
WO2015110048A1 (en)	2014-01-23	2015-07-30	Sunshine Lake Pharma Co., Ltd.	Bridged ring compounds as hepatitis c virus inhibitors, pharmaceutical compositions and uses thereof
CN104860931A (zh)	2014-02-21	2015-08-26	常州寅盛药业有限公司	丙肝病毒抑制剂及其制药用途
CN104860935A (zh) *	2014-02-21	2015-08-26	常州寅盛药业有限公司	作为丙肝病毒抑制剂的噻吩或其变体衍生物及其制药用途
WO2015184644A1 (zh) *	2014-06-06	2015-12-10	爱博新药研发(上海)有限公司	抑制丙肝病毒的化合物、药物组合物及其应用
TWI721947B (zh)	2014-06-11	2021-03-21	美商基利法瑪席特有限責任公司	抗病毒化合物的固態形式
CN104140417B (zh) *	2014-06-11	2016-04-06	苏州景泓生物技术有限公司	合成gs5885用的中间体的先期化合物的合成方法
CN105524049B (zh) *	2014-09-28	2018-11-06	正大天晴药业集团股份有限公司	氘代的丙型肝炎病毒ns5a蛋白抑制剂
CN104513147B (zh) *	2014-11-20	2016-05-11	上海众强药业有限公司	芴乙酮衍生物的制备方法
TWI675029B (zh) *	2014-12-16	2019-10-21	大陸商廣東東陽光藥業有限公司	作為丙型肝炎抑制劑的橋環化合物及其製備方法
WO2016103232A1 (en) *	2014-12-24	2016-06-30	Granules India Limited	An improved process for the preparation of hcv inhibitor
CN104530016A (zh) *	2014-12-25	2015-04-22	上海泓博智源医药技术有限公司	一种雷迪帕韦的制备方法及其中间体
HRP20211456T1 (hr)	2014-12-26	2021-12-24	Emory University	Protuvirusni derivati n4-hidroksicitidina
AU2016217952A1 (en)	2015-02-13	2017-09-28	Sandoz Ag	Pharmaceutical compositions comprising Ledipasvir and Sofosbuvir
CN105985355B (zh) *	2015-03-01	2020-05-05	南京圣和药业股份有限公司	稠合三环类肝炎病毒抑制剂及其应用
EP3722297A1 (en)	2015-03-04	2020-10-14	Gilead Sciences, Inc.	Toll-like receptor modulating 4,6-diamino-pyrido[3,2-d]pyrimidine compounds
WO2016145269A1 (en)	2015-03-12	2016-09-15	Teva Pharmaceuticals International Gmbh	Solid state forms ledipasvir and processes for preparation of ledipasvir
CN104829599B (zh) *	2015-03-17	2017-06-09	上海众强药业有限公司	雷迪帕韦及其衍生物的制备方法及用于制备雷迪帕韦的中间体化合物
US20160375017A1 (en)	2015-06-26	2016-12-29	Abbvie Inc.	Solid Pharmaceutical Compositions for Treating HCV
CN105017228A (zh) *	2015-07-03	2015-11-04	上海众强药业有限公司	一种雷迪帕韦中间体单硫酸盐、其晶型及其制备方法
PE20180928A1 (es)	2015-07-24	2018-06-08	Newlink Genetics Corp	Sales y profarmacos de 1-metil-d-triptofano
WO2017023631A1 (en)	2015-08-06	2017-02-09	Bristol-Myers Squibb Company	Hepatitis c virus inhibitors
KR101919194B1 (ko) *	2015-09-15	2018-11-15	주식회사 엘지화학	헤테로고리 화합물 및 이를 포함하는 유기 발광 소자
CN105294713A (zh) *	2015-10-09	2016-02-03	重庆康施恩化工有限公司	Velpatasvir中间体及其制备方法
WO2017072596A1 (en) *	2015-10-26	2017-05-04	Optimus Drugs (P) Ltd	An improved process for the preparation of ledipasvir
WO2017072714A1 (en)	2015-10-30	2017-05-04	Lupin Limited	Stable ledipasvir premix and process of preparation thereof
CN108349945B (zh) *	2015-11-06	2021-10-29	江苏豪森药业集团有限公司	Hcv抑制剂、其制备方法与应用
CN106117187B (zh) *	2016-01-12	2019-01-01	深圳市塔吉瑞生物医药有限公司	一种丙型肝炎病毒抑制剂、药物组合物及其应用
WO2017134548A1 (en)	2016-02-01	2017-08-10	Lupin Limited	Process for the preparation of ledipasvir and intermediates thereof
WO2017145028A1 (en) *	2016-02-26	2017-08-31	Glenmark Pharmaceuticals Limited	Process for preparation of ledipasvir
WO2017184670A2 (en)	2016-04-22	2017-10-26	Gilead Sciences, Inc.	Methods for treating zika virus infections
EP3448392A4 (en)	2016-04-28	2020-01-15	Emory University	ALCYNE-CONTAINING NUCLEOTIDES AND NUCLEOSIDES THERAPEUTIC COMPOSITIONS AND USES THEREOF
EP4483875A2 (en)	2016-05-10	2025-01-01	C4 Therapeutics, Inc.	Spirocyclic degronimers for target protein degradation
WO2017197051A1 (en)	2016-05-10	2017-11-16	C4 Therapeutics, Inc.	Amine-linked c3-glutarimide degronimers for target protein degradation
WO2017197046A1 (en)	2016-05-10	2017-11-16	C4 Therapeutics, Inc.	C3-carbon linked glutarimide degronimers for target protein degradation
CN109562107A (zh)	2016-05-10	2019-04-02	C4医药公司	用于靶蛋白降解的杂环降解决定子体
WO2017195147A1 (en)	2016-05-12	2017-11-16	Lupin Limited	Process for the preparation of ledipasvir and intermediates thereof
CN109414508A (zh)	2016-05-27	2019-03-01	吉利德科学公司	使用ns5a、ns5b或ns3抑制剂治疗乙型肝炎病毒感染的方法
BR102017011025A2 (pt)	2016-06-02	2017-12-19	Gilead Pharmasset Llc	Formulation of combination of three antiviral compounds
CN107663196A (zh) *	2016-07-27	2018-02-06	广东东阳光药业有限公司	制备化合物的方法
WO2018035410A1 (en) *	2016-08-19	2018-02-22	Temple University-Of The Commonwealth System Of Higher Education	Compositions and methods of treatment using expanded-size dna analogs
EP3507288B1 (en)	2016-09-02	2020-08-26	Gilead Sciences, Inc.	4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators
PL3507276T3 (pl)	2016-09-02	2022-02-21	Gilead Sciences, Inc.	Związki modulatory receptorów toll-podobnych
CN106632275B (zh) *	2016-12-20	2018-03-06	上海同昌生物医药科技有限公司	一种雷迪帕韦的制备方法及制备雷迪帕韦的中间体
RU2650610C1 (ru)	2017-02-28	2018-04-16	Васильевич Иващенко Александр	Противовирусная композиция и способ ее применения
US10392370B2 (en)	2017-03-13	2019-08-27	Optimus Drugs Pvt Ltd	Process for the preparation of Daclatasvir dihydrochloride and its intermediates
JOP20180040A1 (ar)	2017-04-20	2019-01-30	Gilead Sciences Inc	مثبطات pd-1/pd-l1
US11472806B2 (en)	2017-05-12	2022-10-18	Domain Therapeutics	Substituted heterocyclic compounds as allosteric modulators of group II metabotropic glutamate receptors
ES2995458T3 (en)	2017-12-07	2025-02-10	Univ Emory	N4-hydroxycytidine derivative and anti-viral uses related thereto
IL300572A (en)	2018-02-13	2023-04-01	Gilead Sciences Inc	PD–1/PD–L1 inhibitors
JP7242702B2 (ja)	2018-04-19	2023-03-20	ギリアードサイエンシーズ，インコーポレイテッド	Ｐｄ－１／ｐｄ－ｌ１阻害剤
JP2021523942A (ja) *	2018-05-15	2021-09-09	ユニバーシティ・オブ・ルイスビル・リサーチ・ファウンデーション・インコーポレイテッドＵｎｉｖｅｒｓｉｔｙＯｆＬｏｕｉｓｖｉｌｌｅＲｅｓｅａｒｃｈＦｏｕｎｄａｔｉｏｎ，Ｉｎｃ．	療法における使用のためのウロリシンａおよびその誘導体
JP7105359B2 (ja)	2018-07-13	2022-07-22	ギリアードサイエンシーズ，インコーポレイテッド	Ｐｄ－１／ｐｄ－ｌ１阻害剤
EP3870566A1 (en)	2018-10-24	2021-09-01	Gilead Sciences, Inc.	Pd-1/pd-l1 inhibitors
WO2020219808A1 (en) *	2019-04-25	2020-10-29	Beta Pharma, Inc.	Dicarbamate inhibitors of ns5a for treatment of hepatitis c virus infections and related diseases
WO2020255038A1 (en)	2019-06-18	2020-12-24	Janssen Sciences Ireland Unlimited Company	Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives
US20230218644A1 (en)	2020-04-16	2023-07-13	Som Innovation Biotech, S.A.	Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
EP4079748A1 (en)	2021-04-23	2022-10-26	Insusense ApS	Modulators of sortilin activity
EP4089102A1 (en)	2021-05-14	2022-11-16	Insusense ApS	Modulators of sortilin activity
WO2022246072A1 (en) *	2021-05-21	2022-11-24	Gilead Sciences, Inc.	Tetracyclic compounds for the treatment of zika virus infection
EP4341266A1 (en)	2021-05-21	2024-03-27	Gilead Sciences, Inc.	Pentacyclic derivatives as zika virus inhibitors
KR20240035513A (ko)	2021-07-09	2024-03-15	알리고스 테라퓨틱스 인코포레이티드	항바이러스 화합물
WO2023043816A1 (en) *	2021-09-17	2023-03-23	Aligos Therapeutics, Inc.	Anti-viral compounds for treating coronavirus, picornavirus, and norovirus infections
EP4476202A1 (en) *	2022-02-11	2024-12-18	Wave Life Sciences Ltd.	Stereoselective technologies for chiral compounds

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4816570A (en)	1982-11-30	1989-03-28	The Board Of Regents Of The University Of Texas System	Biologically reversible phosphate and phosphonate protective groups
US4968788A (en)	1986-04-04	1990-11-06	Board Of Regents, The University Of Texas System	Biologically reversible phosphate and phosphonate protective gruops
ATE131825T1 (de)	1990-06-13	1996-01-15	Arnold Glazier	Phosphorylierte prodrugs
DK0481214T3 (da)	1990-09-14	1999-02-22	Acad Of Science Czech Republic	Prolægemidler af phosphonater
US5543523A (en)	1994-11-15	1996-08-06	Regents Of The University Of Minnesota	Method and intermediates for the synthesis of korupensamines
PL382845A1 (pl)	2004-07-16	2008-01-21	Gilead Sciences, Inc.	Związki przeciwwirusowe
US7323447B2 (en) *	2005-02-08	2008-01-29	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US8143288B2 (en) *	2005-06-06	2012-03-27	Bristol-Myers Squibb Company	Inhibitors of HCV replication
US7659270B2 (en) *	2006-08-11	2010-02-09	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US8303944B2 (en) *	2006-08-11	2012-11-06	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US8329159B2 (en) *	2006-08-11	2012-12-11	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US7759495B2 (en)	2006-08-11	2010-07-20	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US7964580B2 (en)	2007-03-30	2011-06-21	Pharmasset, Inc.	Nucleoside phosphoramidate prodrugs
US7741347B2 (en) *	2007-05-17	2010-06-22	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
EP2168959A1 (en) *	2007-06-19	2010-03-31	Kyorin Pharmaceutical Co., Ltd.	Pyridazinone derivative and pde inhibitor containing the same as active ingredient
US7728027B2 (en)	2007-08-08	2010-06-01	Bristol-Myers Squibb Company	Process for synthesizing compounds useful for treating hepatitis C
US8629171B2 (en)	2007-08-08	2014-01-14	Bristol-Myers Squibb Company	Crystalline form of methyl ((1S)-1-((25)-2-(5-(4'-(2-((25)-1((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt
NZ587323A (en)	2008-02-12	2012-02-24	Bristol Myers Squibb Co	Hepatitis c virus inhibitors
US8147818B2 (en)	2008-02-13	2012-04-03	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US7704992B2 (en) *	2008-02-13	2010-04-27	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
PT2242752E (pt)	2008-02-13	2012-10-29	Bristol Myers Squibb Co	Imidazolil bifenil imidazóis como inibidores do vírus da hepatite c
GB2457659A (en)	2008-02-19	2009-08-26	Malcolm Mulheron	Foldable meal tray
WO2010004843A1 (ja)	2008-07-08	2010-01-14	Ntn株式会社	減速装置
JP2011527331A (ja)	2008-07-10	2011-10-27	プロシディオン・リミテッド	ピペリジニルｇｐｃｒ作動薬
US7906655B2 (en)	2008-08-07	2011-03-15	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US8383094B2 (en) *	2008-10-01	2013-02-26	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US8729077B2 (en)	2008-11-28	2014-05-20	Glaxosmithkline Llc	Anti-viral compounds, compositions, and methods of use
US9120779B2 (en)	2008-12-03	2015-09-01	Presidio Pharmaceuticals, Inc.	Inhibitors of HCV NS5A
DK2373172T3 (da) *	2008-12-03	2013-10-21	Presidio Pharmaceuticals Inc	Hcv-ns5a-hæmmere
EP2393359A4 (en)	2009-02-09	2012-10-03	Enanta Pharm Inc	COMPOUND DIBENZIMIDAZOLE DERIVATIVES
WO2010096462A1 (en)	2009-02-17	2010-08-26	Enanta Pharmaceuticals, Inc	Linked diimidazole derivatives
TWI438200B (zh)	2009-02-17	2014-05-21	必治妥美雅史谷比公司	Ｃ型肝炎病毒抑制劑
UY32462A (es)	2009-02-23	2010-09-30	Arrow Therapeutics Ltd	Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644
US20120040977A1 (en)	2009-02-23	2012-02-16	Presidio Pharmaceuticals, Inc.	Inhibitors of hcv ns5a
JP5628841B2 (ja)	2009-02-27	2014-11-19	エナンタファーマシューティカルズインコーポレイテッド	Ｃ型肝炎ウイルスインヒビター
US20100249068A1 (en)	2009-03-20	2010-09-30	Alios Biopharma, Inc.	Substituted nucleoside and nucleotide analogs
PE20120773A1 (es)	2009-03-27	2012-07-19	Presidio Pharmaceuticals Inc	Anillos triciclicos fusionados sustituidos como inhibidores del virus de hepatitis c
EP2410841A4 (en)	2009-03-27	2012-10-24	Presidio Pharmaceuticals Inc	SUBSTITUTED BICYCLIC HCV INHIBITORS
EP2410844B1 (en)	2009-03-27	2016-03-23	Merck Sharp & Dohme Corp.	Inhibitors of hepatitis c virus replication
TWI476190B (zh) *	2009-03-30	2015-03-11	必治妥美雅史谷比公司	Ｃ型肝炎病毒抑制劑
US8796466B2 (en) *	2009-03-30	2014-08-05	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
TW201038559A (en)	2009-04-09	2010-11-01	Bristol Myers Squibb Co	Hepatitis C virus inhibitors
US8143414B2 (en)	2009-04-13	2012-03-27	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
JP5734956B2 (ja)	2009-04-15	2015-06-17	アッヴィ・インコーポレイテッド	抗ウィルス化合物
AU2010240882B2 (en)	2009-04-24	2014-10-23	Janssen Sciences Ireland Uc	Diaryl ethers
CA2760205A1 (en) *	2009-05-12	2010-11-18	Schering Corporation	Fused tricyclic aryl compounds useful for the treatment of viral diseases
SI2430014T1 (sl)	2009-05-13	2015-10-30	Gilead Pharmasset Llc	Protivirusne spojine
EP2435421A1 (en)	2009-05-29	2012-04-04	Schering Corporation	Antiviral compounds composed of three aligned aryl moieties to treat diseases such as hepatitis c
US8138215B2 (en)	2009-05-29	2012-03-20	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US8211928B2 (en)	2009-05-29	2012-07-03	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
EP2435424B1 (en)	2009-05-29	2015-01-21	Merck Sharp & Dohme Corp.	Antiviral compounds composed of three linked aryl moieties to treat diseases such as hepatitis c
RS53856B1 (en)	2009-06-11	2015-08-31	Abbvie Bahamas Ltd.	HETEROCYCLIC COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS
WO2010148006A1 (en)	2009-06-16	2010-12-23	Enanta Pharmaceuticals, Inc.	Hepatitis c virus inhibitors
US8221737B2 (en) *	2009-06-16	2012-07-17	Enanta Pharmaceuticals, Inc.	Hepatitis C virus inhibitors
WO2011004276A1 (en)	2009-07-06	2011-01-13	Pfizer Limited	Hepatitis c virus inhibitors
EP2454254A2 (en)	2009-07-16	2012-05-23	Vertex Pharmaceuticals Incorporated	Benzimidazole analogues for the treatment or prevention of flavivirus infections
EP2462136A1 (en)	2009-08-07	2012-06-13	Janssen R&D Ireland	Phenyl ethynyl derivatives as hepatitis c virus inhibitors
CA2768638A1 (en)	2009-08-07	2011-02-10	Tibotec Pharmaceuticals	Bis-benzimidazole derivatives as hepatitis c virus inhibitors
FR2949465B1 (fr)	2009-09-01	2011-08-12	Pf Medicament	Derives chromones, leur procede de preparation et leurs applications therapeutiques
BR112012004969A2 (pt)	2009-09-03	2019-09-24	Tibotec Pharm Ltd	derivados de bis-benzimidazol
WO2011028596A1 (en)	2009-09-04	2011-03-10	Glaxosmithkline Llc	Chemical compounds
WO2011031904A1 (en)	2009-09-11	2011-03-17	Enanta Pharmaceuticals, Inc	Hepatitis c virus inhibitors
WO2011031934A1 (en)	2009-09-11	2011-03-17	Enanta Pharmaceuticals, Inc.	Hepatitis c virus inhibitors
US8415374B2 (en)	2009-10-12	2013-04-09	Bristol-Myers Squibb Company	Combinations of hepatitis C virus inhibitors
WO2011050146A1 (en)	2009-10-23	2011-04-28	Glaxosmithkline Llc	Chemical compounds
UA108211C2 (uk)	2009-11-04	2015-04-10	Янссен Рід Айрленд	Бензімідазолімідазольні похідні
US20110274648A1 (en)	2009-11-11	2011-11-10	Bristol-Myers Squibb Company	Hepatitis C Virus Inhibitors
US20110269956A1 (en)	2009-11-11	2011-11-03	Bristol-Myers Squibb Company	Hepatitis C Virus Inhibitors
US20110281910A1 (en)	2009-11-12	2011-11-17	Bristol-Myers Squibb Company	Hepatitis C Virus Inhibitors
CA2782024A1 (en)	2009-11-25	2011-06-03	Schering Corporation	Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases
US20110137633A1 (en) *	2009-12-03	2011-06-09	Abbott Laboratories	Anti-viral compounds and methods of identifying the same
WO2011081918A1 (en) *	2009-12-14	2011-07-07	Enanta Pharmaceuticals, Inc	Hepatitis c virus inhibitors
US8377980B2 (en)	2009-12-16	2013-02-19	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
CN102791687B (zh)	2009-12-18	2015-02-11	北京凯因科技股份有限公司	C型肝炎病毒复制的新型抑制剂
AU2010330862B2 (en) *	2009-12-18	2015-06-25	Idenix Pharmaceuticals, Inc.	5,5-fused arylene or heteroarylene hepatitis C virus inhibitors
AU2010341537A1 (en)	2009-12-22	2012-08-09	Merck Sharp & Dohme Corp.	Fused Tricyclic Compounds and methods of use thereof for the treatment of viral diseases
CN102883718A (zh)	2009-12-24	2013-01-16	顶点制药公司	用于治疗或预防黄病毒感染的类似物
US8362020B2 (en)	2009-12-30	2013-01-29	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
WO2011091446A1 (en)	2010-01-22	2011-07-28	Glaxosmithkline Llc	Chemical compounds
JP2013522202A (ja)	2010-03-09	2013-06-13	メルク・シャープ・エンド・ドーム・コーポレイション	縮合三環式シリル化合物およびウイルス疾患の治療のためのその使用方法
US20110312996A1 (en)	2010-05-17	2011-12-22	Intermune, Inc.	Novel inhibitors of hepatitis c virus replication
WO2011146817A1 (en) *	2010-05-21	2011-11-24	Gilead Sciences, Inc.	Heterocyclic flaviviridae virus inhibitors
TW201211047A (en) *	2010-06-10	2012-03-16	Gilead Sciences Inc	Methods for treating HCV
BR112013004520A2 (pt)	2010-08-26	2016-06-07	Univ Emory	inibidores potentes e seletivos do virus da hepatite c
WO2012041014A1 (en)	2010-09-29	2012-04-05	Merck Sharp & Dohme Corp.	Tetracyclic indole derivatives for treating hepatitis c virus infection
WO2012048421A1 (en)	2010-10-14	2012-04-19	Boehringer Ingelheim International Gmbh	Hepatitis c inhibitor compounds
SG10201509456SA (en)	2010-11-17	2015-12-30	Gilead Pharmasset Llc	Antiviral compounds
TW201306841A (zh)	2010-12-20	2013-02-16	Gilead Sciences Inc	治療ｃ型肝炎病毒（ｈｃｖ）之方法
WO2012087976A2 (en)	2010-12-21	2012-06-28	Intermune, Inc.	Novel inhibitors of hepatitis c virus replication
PE20141056A1 (es) *	2011-09-16	2014-09-05	Gilead Pharmasset Llc	Metodos para el tratamiento de vhc
PT3431477T (pt)	2011-11-16	2020-12-15	Gilead Pharmasset Llc	Imidazolilimidazolos condensados como compostos antivirais
US8969588B2 (en) *	2012-06-05	2015-03-03	Gilead Pharmasset Llc	Solid forms of an antiviral compound
US8841340B2 (en) *	2012-08-17	2014-09-23	Gilead Sciences, Inc.	Solid forms of an antiviral compound

2010
- 2010-05-12 SI SI201031024T patent/SI2430014T1/sl unknown
- 2010-05-12 PL PL15180635T patent/PL3002281T3/pl unknown
- 2010-05-12 WO PCT/US2010/034600 patent/WO2010132601A1/en active Application Filing
- 2010-05-12 EP EP17190692.8A patent/EP3309157B1/en active Active
- 2010-05-12 EP EP19193481.9A patent/EP3626716A1/en not_active Withdrawn
- 2010-05-12 TW TW099115093A patent/TWI465444B/zh active
- 2010-05-12 EP EP14175539.7A patent/EP2873665B1/en active Active
- 2010-05-12 TW TW109105841A patent/TW202042807A/zh unknown
- 2010-05-12 DK DK15180635.3T patent/DK3002281T3/en active
- 2010-05-12 PT PT107209702T patent/PT2430014E/pt unknown
- 2010-05-12 ME MEP-2017-262A patent/ME02916B/me unknown
- 2010-05-12 PL PL10720970T patent/PL2430014T3/pl unknown
- 2010-05-12 KR KR1020197007083A patent/KR20190029771A/ko active Application Filing
- 2010-05-12 KR KR1020117029699A patent/KR101546119B1/ko active Protection Beyond IP Right Term
- 2010-05-12 TW TW104133224A patent/TW201617073A/zh unknown
- 2010-05-12 ES ES10720970.2T patent/ES2548156T3/es active Active
- 2010-05-12 KR KR1020207001908A patent/KR20200011049A/ko not_active Application Discontinuation
- 2010-05-12 EA EA201190259A patent/EA021974B1/ru active Protection Beyond IP Right Term
- 2010-05-12 MX MX2011012058A patent/MX2011012058A/es active IP Right Grant
- 2010-05-12 KR KR1020187006008A patent/KR20180028070A/ko not_active Application Discontinuation
- 2010-05-12 PL PL17190692T patent/PL3309157T3/pl unknown
- 2010-05-12 CN CN201811070551.XA patent/CN109020961A/zh active Pending
- 2010-05-12 CN CN201410227599.2A patent/CN104016971B/zh active Active
- 2010-05-12 TW TW105117036A patent/TWI629981B/zh active
- 2010-05-12 LT LTEP15180635.3T patent/LT3002281T/lt unknown
- 2010-05-12 RS RS20160824A patent/RS55249B8/sr unknown
- 2010-05-12 SI SI201031290T patent/SI2873665T1/sl unknown
- 2010-05-12 TW TW103134405A patent/TW201503888A/zh unknown
- 2010-05-12 ME MEP-2016-215A patent/ME02536B/me unknown
- 2010-05-12 KR KR1020147016504A patent/KR101503752B1/ko active IP Right Grant
- 2010-05-12 HU HUE10720970A patent/HUE025983T2/en unknown
- 2010-05-12 DK DK10720970.2T patent/DK2430014T3/en active
- 2010-05-12 MX MX2014006862A patent/MX363732B/es unknown
- 2010-05-12 SI SI201031554T patent/SI3002281T1/sl unknown
- 2010-05-12 EP EP20140175570 patent/EP2857394A1/en not_active Withdrawn
- 2010-05-12 HU HUE15180635A patent/HUE036906T2/hu unknown
- 2010-05-12 NZ NZ61920510A patent/NZ619205A/en unknown
- 2010-05-12 ES ES17190692T patent/ES2758726T3/es active Active
- 2010-05-12 CN CN201611104976.9A patent/CN106588890B/zh active Active
- 2010-05-12 CN CN201410226959.7A patent/CN104211689B/zh active Active
- 2010-05-12 CN CN201410226767.6A patent/CN104230900B/zh active Active
- 2010-05-12 EA EA201490853A patent/EA201490853A1/ru unknown
- 2010-05-12 AU AU2010249043A patent/AU2010249043B2/en active Active
- 2010-05-12 EA EA201790515A patent/EA037281B1/ru unknown
- 2010-05-12 MX MX2014005933A patent/MX360800B/es unknown
- 2010-05-12 NO NO15180635A patent/NO3002281T3/no unknown
- 2010-05-12 PE PE2011001965A patent/PE20120509A1/es active IP Right Grant
- 2010-05-12 SM SM20170570T patent/SMT201700570T1/it unknown
- 2010-05-12 SG SG10201402280QA patent/SG10201402280QA/en unknown
- 2010-05-12 TW TW107113373A patent/TWI689305B/zh active
- 2010-05-12 ES ES14175539.7T patent/ES2596247T3/es active Active
- 2010-05-12 UY UY0001032629A patent/UY32629A/es not_active Application Discontinuation
- 2010-05-12 ES ES15180635.3T patent/ES2646131T3/es active Active
- 2010-05-12 PE PE2014001982A patent/PE20150202A1/es active IP Right Grant
- 2010-05-12 DK DK14175539.7T patent/DK2873665T3/en active
- 2010-05-12 RS RS20150758A patent/RS54386B8/sr unknown
- 2010-05-12 EP EP15180635.3A patent/EP3002281B1/en active Active
- 2010-05-12 BR BRPI1010795A patent/BRPI1010795B1/pt active IP Right Grant
- 2010-05-12 AP AP2016008993A patent/AP2016008993A0/xx unknown
- 2010-05-12 NZ NZ596444A patent/NZ596444A/en unknown
- 2010-05-12 PT PT171906928T patent/PT3309157T/pt unknown
- 2010-05-12 LT LTEP14175539.7T patent/LT2873665T/lt unknown
- 2010-05-12 BR BR122014012810A patent/BR122014012810B1/pt active IP Right Grant
- 2010-05-12 SG SG2011083151A patent/SG176015A1/en unknown
- 2010-05-12 KR KR1020147016501A patent/KR20140122705A/ko not_active Application Discontinuation
- 2010-05-12 ME MEP-2015-196A patent/ME02321B/me unknown
- 2010-05-12 SI SI201031950T patent/SI3309157T1/sl unknown
- 2010-05-12 EP EP10720970.2A patent/EP2430014B1/en active Active
- 2010-05-12 KR KR1020177009423A patent/KR20170041924A/ko not_active Application Discontinuation
- 2010-05-12 EA EA201490854A patent/EA026536B1/ru unknown
- 2010-05-12 US US12/779,023 patent/US8088368B2/en active Active
- 2010-05-12 BR BR122014013631A patent/BR122014013631B8/pt active IP Right Grant
- 2010-05-12 AR ARP100101639A patent/AR076765A1/es not_active Application Discontinuation
- 2010-05-12 CA CA2761258A patent/CA2761258C/en active Active
- 2010-05-12 RS RS20171281A patent/RS56654B8/sr unknown
- 2010-05-12 PL PL14175539T patent/PL2873665T3/pl unknown
- 2010-05-12 CN CN201080029503.1A patent/CN102596936B/zh active Active
- 2010-05-12 EA EA201590073A patent/EA027493B1/ru unknown
- 2010-05-12 PT PT141755397T patent/PT2873665T/pt unknown
- 2010-05-12 UA UAA201413049A patent/UA121454C2/uk unknown
- 2010-05-12 MX MX2014005805A patent/MX360803B/es unknown
- 2010-05-12 HU HUE14175539A patent/HUE030465T2/hu unknown
- 2010-05-12 PT PT151806353T patent/PT3002281T/pt unknown
- 2010-05-12 CN CN201410226164.6A patent/CN103977406B/zh active Active
- 2010-05-12 CN CN201410227574.2A patent/CN104211713B/zh active Active
- 2010-05-12 KR KR1020167017466A patent/KR101727876B1/ko active IP Right Grant
- 2010-05-12 NZ NZ706236A patent/NZ706236A/en unknown
- 2010-05-12 TW TW103134406A patent/TWI547495B/zh active
- 2010-05-12 AP AP2011005987A patent/AP3622A/xx active
- 2010-05-12 JP JP2012510987A patent/JP5582662B2/ja active Active
- 2010-05-12 CA CA2886322A patent/CA2886322A1/en not_active Abandoned
2011
- 2011-11-08 US US13/291,977 patent/US8273341B2/en active Active
- 2011-11-10 IL IL216254A patent/IL216254A/en active IP Right Grant
- 2011-11-11 MX MX2020011251A patent/MX2020011251A/es unknown
- 2011-11-11 CL CL2011002825A patent/CL2011002825A1/es unknown
- 2011-11-11 MX MX2019003738A patent/MX2019003738A/es active IP Right Grant
- 2011-11-17 ZA ZA2011/08436A patent/ZA201108436B/en unknown
- 2011-11-30 CO CO11164618A patent/CO6470842A2/es active IP Right Grant
- 2011-12-12 EC EC2011011517A patent/ECSP11011517A/es unknown
2012
- 2012-04-02 HK HK15108271.6A patent/HK1207638A1/zh unknown
- 2012-04-02 HK HK12103256.9A patent/HK1162518A1/zh unknown
- 2012-06-07 US US13/491,446 patent/US8669234B2/en active Active
- 2012-07-19 US US13/553,517 patent/US8575118B2/en active Active
2013
- 2013-07-31 US US13/956,195 patent/US8822430B2/en active Active
- 2013-10-03 US US14/045,717 patent/US8841278B2/en active Active
2014
- 2014-05-16 US US14/280,478 patent/US9511056B2/en active Active
- 2014-05-23 JP JP2014107359A patent/JP5744283B2/ja active Active
- 2014-06-10 IL IL233044A patent/IL233044A/en active IP Right Grant
- 2014-06-10 IL IL233042A patent/IL233042A0/en unknown
- 2014-06-17 JP JP2014124325A patent/JP5745727B2/ja active Active
- 2014-07-17 IL IL233679A patent/IL233679B/en active IP Right Grant
- 2014-07-17 IL IL233678A patent/IL233678B/en active IP Right Grant
2015
- 2015-04-28 JP JP2015091474A patent/JP2015157842A/ja not_active Withdrawn
- 2015-09-22 HR HRP20151000TT patent/HRP20151000T8/hr unknown
- 2015-11-17 CY CY20151101032T patent/CY1116942T1/el unknown
- 2015-11-19 SM SM201500284T patent/SMT201500284B/it unknown
2016
- 2016-01-07 HU HUS1600001C patent/HUS1600001I1/hu unknown
- 2016-01-11 LT LTPA2016002C patent/LTC2430014I2/lt unknown
- 2016-01-22 CY CY2016001C patent/CY2016001I2/el unknown
- 2016-02-05 FR FR16C0005C patent/FR16C0005I2/fr active Active
- 2016-02-17 NO NO2016004C patent/NO2016004I2/no not_active IP Right Cessation
- 2016-02-18 NL NL300796C patent/NL300796I2/nl unknown
- 2016-09-28 US US15/279,303 patent/US9981955B2/en active Active
- 2016-09-29 HR HRP20161242TT patent/HRP20161242T8/hr unknown
- 2016-10-04 CY CY20161100986T patent/CY1118048T1/el unknown
- 2016-10-05 SM SM201600351T patent/SMT201600351B/it unknown
- 2016-10-06 HK HK16111614.5A patent/HK1223365A1/zh unknown
2017
- 2017-05-12 JP JP2017095523A patent/JP2017145254A/ja not_active Withdrawn
- 2017-11-14 HR HRP20171759TT patent/HRP20171759T8/hr unknown
- 2017-12-06 CY CY20171101286T patent/CY1119684T1/el unknown
2018
- 2018-10-05 HK HK18112717.7A patent/HK1253517B/zh unknown
- 2018-12-25 JP JP2018240826A patent/JP2019104732A/ja not_active Withdrawn
2020
- 2020-09-24 JP JP2020159623A patent/JP2021001214A/ja active Pending
- 2020-12-18 NO NO2020046C patent/NO2020046I1/no unknown

Also Published As

Publication number	Publication date
AP2016008993A0 (en)	2016-01-31
EP2430014B1 (en)	2015-08-19
ME02321B (me)	2016-06-20
AU2010249043A1 (en)	2011-12-01
JP5745727B2 (ja)	2015-07-08
DK3002281T3 (en)	2017-12-18
NZ706236A (en)	2016-07-29
CN104016971B (zh)	2016-05-25
EP2873665A1 (en)	2015-05-20
TWI629981B (zh)	2018-07-21
HK1162518A1 (zh)	2012-08-31
KR20180028070A (ko)	2018-03-15
RS55249B1 (sr)	2017-02-28
EP3626716A1 (en)	2020-03-25
KR20140122706A (ko)	2014-10-20
SG10201402280QA (en)	2014-08-28
TW202042807A (zh)	2020-12-01
JP5744283B2 (ja)	2015-07-08
CN102596936B (zh)	2014-06-11
US9981955B2 (en)	2018-05-29
SI3002281T1 (sl)	2017-11-30
EP2857394A1 (en)	2015-04-08
TW201902477A (zh)	2019-01-16
KR101546119B1 (ko)	2015-08-20
JP2019104732A (ja)	2019-06-27
AP2011005987A0 (en)	2011-12-31
TWI465444B (zh)	2014-12-21
WO2010132601A1 (en)	2010-11-18
CO6470842A2 (es)	2012-06-29
CN104211713A (zh)	2014-12-17
UA121454C2 (uk)	2020-06-10
EP2873665B1 (en)	2016-07-06
HUE025983T2 (en)	2016-05-30
DK2430014T3 (en)	2015-11-30
BR122014013631B1 (pt)	2020-11-17
HRP20151000T1 (hr)	2015-11-20
BR122014013631B8 (pt)	2021-11-23
IL233678A0 (en)	2014-09-30
MX2019003738A (es)	2019-07-01
US20170029408A1 (en)	2017-02-02
EA027493B1 (ru)	2017-07-31
US20140051656A1 (en)	2014-02-20
ES2596247T3 (es)	2017-01-05
BR122014012810B1 (pt)	2020-04-14
IL216254A0 (en)	2012-01-31
HRP20161242T8 (hr)	2021-05-14
BRPI1010795B1 (pt)	2018-12-11
HRP20161242T1 (hr)	2016-11-18
NZ596444A (en)	2014-01-31
SMT201500284B (it)	2016-01-08
LTPA2016002I1 (lt)	2021-01-11
KR20190029771A (ko)	2019-03-20
CA2761258A1 (en)	2010-11-18
CN106588890B (zh)	2020-11-27
EP2430014A1 (en)	2012-03-21
AU2010249043B2 (en)	2014-10-09
RS55249B8 (sr)	2021-06-30
ES2758726T3 (es)	2020-05-06
NL300796I2 (zh)	2016-06-30
HUS1600001I1 (hu)	2016-02-29
MX2011012058A (es)	2012-04-02
KR101503752B1 (ko)	2015-03-18
DK2873665T3 (en)	2016-11-07
KR20160084478A (ko)	2016-07-13
CN104211689B (zh)	2017-01-18
KR20140122705A (ko)	2014-10-20
FR16C0005I1 (zh)	2016-03-25
PT3309157T (pt)	2019-12-02
SI2873665T1 (sl)	2017-02-28
HK1223365A1 (zh)	2017-07-28
EA201790515A1 (ru)	2018-10-31
JP2012526838A (ja)	2012-11-01
US20100310512A1 (en)	2010-12-09
EA037281B1 (ru)	2021-03-04
HK1253517A1 (zh)	2019-06-21
EP3309157B1 (en)	2019-09-04
CY1116942T1 (el)	2017-04-05
EA201590073A1 (ru)	2015-06-30
US20120264711A1 (en)	2012-10-18
JP2014169331A (ja)	2014-09-18
IL233042A0 (en)	2014-07-31
CN104230900A (zh)	2014-12-24
MX2020011251A (es)	2020-11-12
UY32629A (es)	2010-12-31
LT2873665T (lt)	2016-10-25
US8575118B2 (en)	2013-11-05
TWI547495B (zh)	2016-09-01
US20120157404A1 (en)	2012-06-21
CY2016001I1 (el)	2018-01-10
PT3002281T (pt)	2017-11-14
CN104211689A (zh)	2014-12-17
CN102596936A (zh)	2012-07-18
HRP20171759T1 (hr)	2017-12-29
PT2873665T (pt)	2016-10-13
ES2548156T3 (es)	2015-10-14
PL3309157T3 (pl)	2020-03-31
JP2017145254A (ja)	2017-08-24
PE20150202A1 (es)	2015-02-13
CN109020961A (zh)	2018-12-18
US20140039021A1 (en)	2014-02-06
SI2430014T1 (sl)	2015-10-30
AP3622A (en)	2016-03-02
US20130137877A1 (en)	2013-05-30
KR101727876B1 (ko)	2017-04-17
CN106588890A (zh)	2017-04-26
JP5582662B2 (ja)	2014-09-03
RS56654B8 (sr)	2021-06-30
CN103977406B (zh)	2016-10-19
PL3002281T3 (pl)	2018-02-28
NZ619205A (en)	2015-04-24
RS56654B1 (sr)	2018-03-30
CA2761258C (en)	2015-08-04
SMT201600351B (it)	2016-11-10
EA026536B1 (ru)	2017-04-28
JP2021001214A (ja)	2021-01-07
KR20140014393A (ko)	2014-02-06
AR076765A1 (es)	2011-07-06
US8841278B2 (en)	2014-09-23
EA201190259A1 (ru)	2013-01-30
CA2886322A1 (en)	2010-11-18
HUE036906T2 (hu)	2018-08-28
HRP20171759T8 (hr)	2021-05-14
CN103977406A (zh)	2014-08-13
IL233678B (en)	2019-05-30
US8822430B2 (en)	2014-09-02
CL2011002825A1 (es)	2012-10-12
CN104211713B (zh)	2017-04-12
ME02916B (me)	2018-10-20
PL2873665T3 (pl)	2017-01-31
BRPI1010795A2 (pt)	2016-12-20
BR122014013631A2 (pt)	2017-06-27
IL233044A0 (en)	2014-07-31
HK1253517B (zh)	2020-04-24
IL216254A (en)	2016-08-31
HRP20151000T8 (hr)	2021-05-14
EA201490854A1 (ru)	2014-09-30
PL2430014T3 (pl)	2016-02-29
CN104230900B (zh)	2018-10-19
ECSP11011517A (es)	2012-01-31
ME02536B (me)	2017-02-20
BR122014012810A2 (pt)	2017-06-27
NO2020046I1 (no)	2020-12-18
CY1118048T1 (el)	2018-03-07
PE20120509A1 (es)	2012-05-09
US8088368B2 (en)	2012-01-03
US9511056B2 (en)	2016-12-06
ES2646131T3 (es)	2017-12-12
NO2016004I1 (no)	2016-02-17
EA201490853A1 (ru)	2014-09-30
US8273341B2 (en)	2012-09-25
KR20200011049A (ko)	2020-01-31
TW201617073A (zh)	2016-05-16
TWI689305B (zh)	2020-04-01
IL233044A (en)	2015-07-30
EA021974B1 (ru)	2015-10-30
US20140249074A1 (en)	2014-09-04
TW201105656A (en)	2011-02-16
MX363732B (es)	2019-04-01
JP2015157842A (ja)	2015-09-03
CY1119684T1 (el)	2018-04-04
IL233679A0 (en)	2014-09-30
EP3002281B1 (en)	2017-09-13
LTC2430014I2 (lt)	2021-02-25
NO3002281T3 (zh)	2018-02-10
PT2430014E (pt)	2015-10-20
EP3002281A1 (en)	2016-04-06
IL233679B (en)	2019-05-30
SI3309157T1 (sl)	2020-02-28
RS54386B1 (en)	2016-04-28
RS54386B8 (sr)	2021-06-30
TW201632183A (zh)	2016-09-16
LT3002281T (lt)	2017-12-11
CN104016971A (zh)	2014-09-03
MX360800B (es)	2018-11-16
TW201504244A (zh)	2015-02-01
JP2014148550A (ja)	2014-08-21
ZA201108436B (en)	2013-01-30
FR16C0005I2 (fr)	2016-09-30
CY2016001I2 (el)	2018-01-10
KR20170041924A (ko)	2017-04-17
US8669234B2 (en)	2014-03-11
HUE030465T2 (hu)	2017-05-29
NO2016004I2 (no)	2016-02-29
SG176015A1 (en)	2011-12-29
EP3309157A1 (en)	2018-04-18
SMT201700570T1 (it)	2018-01-11
MX360803B (es)	2018-11-16
TW201503888A (zh)	2015-02-01

Publication	Publication Date	Title
HK1253517A1 (zh)	2019-06-21	抗病毒化合物
IL219965A0 (en)	2012-07-31	Novel antiviral compounds
IL216026A0 (en)	2012-01-31	Heterocyckic antiviral compounds
GB0908677D0 (en)	2009-08-12	Antiviral compounds
GB0914473D0 (en)	2009-09-30	Antiviral compounds
GB0906209D0 (en)	2009-05-20	Antiviral compounds
ZA201203613B (en)	2013-08-28	Novel antiviral compounds
GB0922520D0 (en)	2010-02-10	Novel antiviral compounds
GB0816600D0 (en)	2008-10-15	Antiviral compounds